Other
Unresectable
0
Pipeline Programs↗
19
Active Trials↗
3
Companies Involved↗
Unresectable is an early-stage landscape with 0 programs across 3 companies. The most active players are AstraZeneca, Bayer, BeiGene.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
61
clinical trials
Completed17 · 28%
Unknown status17 · 28%
Recruiting14 · 23%
Terminated6 · 10%
Not yet recruiting3 · 5%
Enrolling by invitation2 · 3%
Other2 · 3%
Clinical Trials
Trial Activity
61 trials
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT05992584·30 enrolled
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Recruiting·—·Phase 1·NCT06463444·30 enrolled
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Recruiting·—·Phase 2·NCT06543069·28 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)